Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent Shigella (Flexneri 2a + Sonnei) conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The bivalent Shigella (Flexneri 2a + Sonnei) conjugate vaccine is a bacterial vaccine developed by Beijing Green Bamboo Biological Pharmacy for the prevention of shigellosis (bacillary dysentery). It is composed of the O-specific polysaccharides (OSP) of *Shigella flexneri* serotype 2a and *Shigella sonnei* individually conjugated to a carrier protein, typically tetanus toxoid (TT). This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, enhancing immunogenicity and inducing immunological memory, which is particularly critical for protection in infants and young children. The vaccine has been evaluated in Phase I and Phase II clinical trials in China to determine optimal dosage, scheduling, and the necessity of adjuvants such as aluminum hydroxide.
- Other names
- Bivalent Shigella dysentery conjugate vaccineShigella flexneri 2a and Shigella sonnei conjugate vaccine
02
Targets
EPA (Pseudomonas aeruginosa Exotoxin A)
Beyond the preview
Go deeper on bivalent Shigella (Flexneri 2a + Sonnei) conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent Shigella (Flexneri 2a + Sonnei) conjugate vaccine.